IP Library Granted Patent US 8,053,205
Granted Patent B2
US 8,053,205 · App. 12/433,111 · Granted Nov 8, 2011

Doxorubicin immunoassay

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,053,205
App. No.
12/433,111
Granted
Nov 8, 2011
Kind
B2
Abstract

Novel conjugates of doxorubicin and novel doxorubicin immunogens derived from the 13 and 14 positions of doxorubicin and antibodies generated by these doxorubicin linked immunogens all of which are useful in immunoassays for the quantification and monitoring of doxorubicin in biological fluids.

Claims (25)

1. An immunoassay for detecting doxorubicin in a sample comprising providing a mixture of a) said sample, b) an antibody selectively reactive with doxorubicin and not substantially cross-reactive with doxorubicin aglycone and c) a conjugate of a carrier having either a reactive thiol or amino group with a compound of the formula:

wherein A is

Y is an organic spacing group;

X is a functional group capable of binding to said carrier through said amino or thiol group; and

p is an integer from 0 to 1;

or a compound of the formula:

wherein X, Y and p are as above and B is —CH 2 — or

or mixtures comprising a conjugate of said carrier with a compound of Formula IIA and a conjugate of said carrier with a compound of Formula IIB;

causing the doxorubicin in the sample and said conjugate in said mixture to bind in said mixture with said antibody and thereafter measuring the amount of said conjugate in said mixture which is bound or unbound to said antibody whereby the presence of doxorubicin in the sample can be determined.

2. The process of claim 1 , wherein the sample is a human sample.

3. The immunoassay of claim 2 , wherein said antibody is generated from an immunogen comprising an immunogenic carrier having a reactive thiol or amino group conjugated to a compound of the formula:

wherein p, X, Y and A are as above;

or a compound of the formula:

wherein p, Y, X and B are as above;

or mixtures thereof.

4. The immunoassay of claim 3 , wherein the compound conjugated to said immunogenic carrier for generating the antibodies has the formula:

wherein p, X, Y and A are as above.

5. The immunoassay of claim 4 , wherein the carrier contains a thiol group and X is the compound which is linked to the immunogenic polymer is a functional group capable of reacting with said thiol.

6. The immunoassay of claim 5 , wherein X is

7. The immunoassay of claim 6 , wherein Y is lower alkyl.

8. The immunoassay of claim 7 wherein the immunogenic carrier contains as the functional group

wherein v is an integer from 1 to 6.

9. The immunoassay of claim 2 , wherein the antibody is attached to a solid support.

10. The immunoassay of claim 9 , wherein the solid support is microtiter plates.

11. The immunoassay of claim 9 , wherein the solid support is nanoparticles.

Assignments (1)
SECURITY INTEREST Recorded Nov 17, 2015
From: SALADAX BIOMEDICAL, INC.
To: SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Reel/Frame 037126/0733 →